Table 1.
Fractionation (tot.dose/fx size/#fx) | Total Dose Equivalent if Given in 2-Gy Fractions (NTD2) | No. of PTS | Institution | References | |
---|---|---|---|---|---|
Alpha/Beta = 1.5 (tumor) | Alpha/Beta = 3 (late complications) | ||||
50 Gy/3.13 Gy/16 fx | 66 Gy | 61.3 Gy | 705 | Christie Hosp, Manchester | Livsey et al24 |
69 Gy/3 Gy/23 fx | 88.7 Gy | 82.8 Gy | 52 | Gunma, Japan | Akimoto et al25 |
66 GyE/3.3 GyE/20 fx (carbon ions) | 90.5 Gy | 83.1 Gy | 201 | NIRS, Chiba, Japan | Tsuji et al26 |
52.5 Gy/2.625 Gy/20 fx | 61.9 Gy | 59.1 Gy | 300 | Edenburgh | Higgins et al27 |
56 Gy/3.5 Gy/16 | 80 Gy | 72.8 Gy | 36 | Jette, Belgium | Soete et al28 |
60 Gy/3 Gy/20 fx | 77.2 Gy | 72 Gy | 92 | Princess Margaret | Martin et al29 |
70 Gy/2.5 Gy/28 fx | 80 Gy | 77 Gy | 770 | Cleveland Clinic | Kupelian et al[19] and [20] |
64.7 Gy/2.94 Gy/22 fx | 82.6 Gy | 77 Gy | 100 | Multi-institutional trial | Ritter et al30 |
58.1 Gy/3.63 Gy/16 fx | 85.1 Gy | 77 Gy | 100 | ||
51.6 Gy/4.3 Gy/12 fx | 85.5 Gy | 75 Gy | 58 (accruing) | ||
52.5/2.625 Gy/20 fx | 61.9 Gy | 59.1 Gy | 466 | NCI-Canada (phase III) | Lukka et al31 |
66 Gy/2 Gy/33 fx | 66 Gy | 66 Gy | 470 | ||
55 Gy/2.75 Gy/20 fx | 66.8 Gy | 63.2 Gy | 108 | Adelaid (phase III) | Yeoh et al32 |
64 Gy/2 Gy/32 fx | 64 Gy | 64 Gy | 109 | ||
70.2 Gy/2.7 Gy/26 fx | 84.2 Gy | 80 Gy | 150 | Fox Chase (phase III) | Pollack et al33 |
76 Gy/2 Gy/38 fx | 76 Gy | 76 Gy | 150 | ||
70 Gy/2.5 Gy/28 fx | 80 Gy | 77 Gy | Ongoing (goal of 1,067 pts) | RTOG 0415(phase III) | www.rtog.org/members/protocols/0415/0415.pdf |
73.8 Gy/1.8 Gy/41 fx | 69.6 Gy | 70.8 Gy | |||
57 Gy/3 Gy/19 fx | 73.3 Gy | 68.4 Gy | Ongoing (goal of 2,100 pts) | MRC (phase III) | Khoo et al34 |
60 Gy/3 Gy/20 fx | 77.2 Gy | 72 Gy |